CLAIMS

1. A compound of general formula (I):



(I)

R^1 represents

- phenyl,
- 5- or 6-membered heteroaryl, wherein said 5-membered heteroaryl contains 1, 2 or 3 heteroatoms or heteroatom-containing groups independently selected from the group consisting of S, N, NH, and O, and wherein said 6-membered heteroaryl contains 1 or 2 nitrogen atoms, or
- bicyclic 8- to 10-membered heteroaryl containing 1, 2 or 3 heteroatoms or heteroatom-containing groups independently selected from NH, N, O, S, SO and SO_2,

wherein said R^1 is optionally substituted at one or more carbon atoms with 1 to 3 substituents R^{1a} which are the same or different, wherein R^{1a} represents C_1-C_5-alkyl, C_3-C_7-cycloalkyl, -(C_1-C_3-alkyl)-(C_3-C_7-cycloalkyl), -OC_1-C_5-alkyl, -OC_3-C_7-cycloalkyl, NHR^4, $N(R^4)_2$, NH(C_3-C_7-cycloalkyl), halogen, CN, $NHSO_2R^4$, SO_2R^4, 5- to 7-membered lactam, or 4- to 7-membered heterocycloalkyl containing 1 or 2 heteroatoms or heteroatom-containing groups selected from NH, -NR^4, N, O, S, SO and SO_2, and

wherein independently, if R^1 represents 5- membered heteroaryl or bicyclic 8- to 10-membered heteroaryl, each ring nitrogen atom, if present, of said R^1 is optionally substituted with a substituent R^{1b}, wherein R^{1b} represents C_1-C_5-alkyl, -(C_1-C_3-alkyl)-(C_3-C_7-cycloalkyl), C_3-C_7-cycloalkyl, SO_2R^4, or 4- to 7-membered heterocycloalkyl containing 1 or 2 heteroatoms

or heteroatom-containing groups selected from NH, -NR^4, N, O, S, SO and SO_2, and

if R^{1a} represents C_1-C_5-alkyl, C_3-C_7-cycloalkyl, -(C_1-C_3-alkyl)-(C_3-C_7-cycloalkyl), -OC_1-C_5-alkyl or -OC_3-C_7-cycloalkyl and/ or if R^{1b} represents C_1-C_5-alkyl, -(C_1-C_3-alkyl)-(C_3-C_7-cycloalkyl), or C_3-C_7-cycloalkyl,

said C_1-C_5-alkyl, C_3-C_7-cycloalkyl, -(C_1-C_3-alkyl)-(C_3-C_7-cycloalkyl), -OC_1-C_5-alkyl and -OC_3-C_7-cycloalkyl independently are optionally substituted with one or more substituents independently selected from the group consisting of methyl, ethyl, OH, OR^4 and F, and

if R^{1a} and/ or R^{1b} represent 4- to 7-membered heterocycloalkyl, each carbon atom of said 4- to 7-membered heterocycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of OH, OR^4 and F;

R^2 represents

- -$(CH_2)_p$-(C_5-C_7-cycloalkyl),
- -$(CH_2)_p$-phenyl,
- 5- or 6-membered heteroaryl wherein said 5-membered heteroaryl contains 1, 2 or 3 heteroatoms or heteroatom-containing groups independently selected from the group consisting of S, N, NH, and O, and wherein said 6-membered heteroaryl contains 1 or 2 nitrogen atoms, or
- bicyclic 8- to 10-membered heteroaryl containing 1, 2 or 3 heteroatoms or heteroatom-containing groups independently selected from NH, N, O, S, SO and SO_2,

wherein said R^2 is optionally substituted at one or more carbon atoms with 1 to 3 substituents R^{2a} which are the same or different, wherein R^{2a} represents C_1-C_5-alkyl, C_3-C_7-cycloalkyl, -(C_1-C_3-alkyl)-(C_3-C_7-cycloalkyl), -OC_1-C_5-alkyl, -OC_3-C_7-cycloalkyl, halogen, OH or CN, and

wherein independently, if R^2 represents 5-membered heteroaryl or bicyclic 8- to 10-membered heteroaryl, each ring nitrogen atom, if present, of said R^2 is optionally substituted with a substituent R^{2b}, wherein R^{2b} represents C_1-C_5-alkyl, C_3-C_7-cycloalkyl or -(C_1-C_3-alkyl)-(C_3-C_7-cycloalkyl), and

if R^{2a} represents C_1-C_5-alkyl, C_3-C_7-cycloalkyl, -(C_1-C_3-alkyl)-(C_3-C_7-cycloalkyl), -OC_1-C_5-alkyl or -OC_3-C_7-cycloalkyl and/or if R^{2b} represents C_1-C_5-alkyl, C_3-C_7-cycloalkyl or -(C_1-C_3-alkyl)-(C_3-C_7-cycloalkyl),

said C_1-C_5-alkyl, C_3-C_7-cycloalkyl, -(C_1-C_3-alkyl)-(C_3-C_7-cycloalkyl), -OC_1-C_5-alkyl and -OC_3-C_7-cycloalkyl independently are optionally substituted with one or more substituents independently selected from the group consisting of OH, OR^4, and F;

p represents 0 or 1;

R^3 represents H or F;

R^4 represents C_1-C_5-alkyl, optionally substituted with 1 to 5 fluorine atoms;

R^5 represents H, halogen, CN, C_1-C_5-alkyl, or -OC_1-C_5-alkyl, wherein said C_1-C_5-alkyl and -OC_1-C_5-alkyl are optionally substituted with 1 to 5 fluorine atoms; and

R^6 and R^7 independently represent H or C_1-C_3-alkyl, wherein said C_1-C_3-alkyl is optionally substituted with 1 to 5 fluorine atoms;

or an enantiomer, diastereomer, racemate, hydrate, solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of the same.

2. The compound according to claim 1, wherein

R^1 represents 5-membered heteroaryl containing 1, 2 or 3 heteroatoms or heteroatom-containing groups independently selected from the group consisting of S, N, NH, and O, in particular pyrazolyl, thiazolyl, imidazolyl or thiophenyl,

wherein said R^1 is optionally substituted at one or more carbon atoms with 1 or 2 substituents R^{1a} which are the same or different, wherein R^{1a} represents C_1-C_5-alkyl, C_3-C_7-cycloalkyl, -(C_1-C_3-alkyl)-(C_3-C_7-cycloalkyl), -OC_1-C_5-alkyl, -OC_3-C_7-cycloalkyl, halogen or CN, and

wherein independently each ring nitrogen atom, if present, of said R^1 is optionally substituted with a substituent R^{1b}, wherein R^{1b} represents C_1-C_5-alkyl, -(C_1-C_3-alkyl)-(C_3-C_7-cycloalkyl) or C_3-C_7-cycloalkyl, and

if R^{1a} represents C_1-C_5-alkyl, C_3-C_7-cycloalkyl, -(C_1-C_3-alkyl)-(C_3-C_7-cycloalkyl), -OC_1-C_5-alkyl or -OC_3-C_7-cycloalkyl and/or if R^{1b} represents C_1-C_5-alkyl, -(C_1-C_3-alkyl)-(C_3-C_7-cycloalkyl) or C_3-C_7-cycloalkyl, said C_1-C_5-alkyl, C_3-C_7-cycloalkyl, -(C_1-C_3-alkyl)-(C_3-C_7-cycloalkyl), -OC_1-C_5-alkyl and -OC_3-C_7-cycloalkyl independently are optionally substituted with one or more substituents independently selected from the group consisting of methyl, ethyl, OH, OR^4 and F;

or an enantiomer diastereomer, racemate, hydrate, solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of the same.

3. The compound according to any one of claims 1 or 2, wherein

R^1 represents pyrazol-4-yl, unsubstituted or substituted at the nitrogen atom at position 1 with a substituent R^{1b}, wherein R^{1b} represents C_1-C_5-alkyl, -(C_1-C_3-alkyl)-(C_3-C_7-cycloalkyl) or C_3-C_7-cycloalkyl, wherein said R^{1b} is optionally substituted with one or more substituents independently selected from the group consisting of methyl, ethyl, OH, OR^4 and F;

or an enantiomer diastereomer, racemate, hydrate, solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of the same.

4. The compound according to any one of claims 1 to 3, wherein

R^2 represents phenyl substituted with 1 or 2 substituents R^{2a} which are the same or different, wherein R^{2a} represents C_1-C_5-alkyl, OC_1-C_5-alkyl, F or Cl,

wherein if the substituent or at least one of said substituents is C_1-C_5-alkyl, -OC_1-C_5-alkyl or Cl, it is preferably positioned para to the carbon atom which links the phenyl to the rest of the molecule, and

wherein said C_1-C_5-alkyl and -OC_1-C_5-alkyl independently are optionally substituted with 1 to 5 fluorine atoms;

or an enantiomer diastereomer, racemate, hydrate, solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of the same.

5. The compound according to any one of claims 1 to 4, wherein

R^6 and R^7 represent H;

or an enantiomer diastereomer, racemate, hydrate, solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of the same.

6. The compound according to any one of claims 1, 2, 4 and 5, wherein

R^1 represents pyrazolyl, in particular pyrazol-4-yl, optionally substituted at one or more carbon atoms with 1 or 2 substituents R^{1a} which are the same or different, wherein R^{1a} represents C_1-C_5-alkyl, C_3-C_7-cycloalkyl, -(C_1-C_3-alkyl)-(C_3-C_7-cycloalkyl), -OC_1-C_5-alkyl, -OC_3-C_7-cycloalkyl, halogen or CN, and

wherein independently each nitrogen atom of said R^1 is optionally substituted with a substituent R^{1b}, wherein R^{1b} represents C_1-C_5-alkyl, -(C_1-C_3-alkyl)-(C_3-C_7-cycloalkyl) or C_3-C_7-cycloalkyl, and

if R^{1a} represents C_1-C_5-alkyl, C_3-C_7-cycloalkyl, -(C_1-C_3-alkyl)-(C_3-C_7-cycloalkyl), -OC_1-C_5-alkyl or -OC_3-C_7-cycloalkyl and/or if R^{1b} represents C_1-C_5-alkyl, -(C_1-C_3-alkyl)-(C_3-C_7-cycloalkyl) or C_3-C_7-cycloalkyl, said C_1-C_5-alkyl, C_3-C_7-cycloalkyl, -(C_1-C_3-alkyl)-(C_3-C_7-cycloalkyl), -OC_1-C_5-alkyl and -OC_3-C_7-cycloalkyl independently are optionally substituted with one or more substituents independently selected from the group consisting of methyl, OH, OR^4 and F;

R^5 represents H, F, Cl or methyl, in particular H or F; and

R^6 and R^7 represent H;

or an enantiomer diastereomer, racemate, hydrate, solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of the same.

7. The compound according to any one of claims 1 to 6, wherein

R^2 represents phenyl substituted with 1 or 2 substituents R^{2a} which are the same or different, wherein R^{2a} represents C_1-C_5-alkyl, -OC_1-C_5-alkyl, F or Cl, and

wherein if the substituent or at least one of said substituents is C_1-C_5-alkyl, -OC_1-C_5-alkyl or Cl, it is preferably positioned para to the carbon atom which links the phenyl to the rest of the molecule, and

wherein said C_1-C_5-alkyl and -OC_1-C_5-alkyl independently are optionally substituted with 1 to 5 fluorine atoms;

R^5 represents H, F, Cl or methyl, in particular H or F; and

R^6 and R^7 represent H;

or an enantiomer diastereomer, racemate, hydrate, solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of the same.

8. The compound according to any one of claims 1, 2, and 4 to 7, wherein

R^1 represents pyrazolyl, in particular pyrazol-4-yl, optionally substituted at one or more carbon atoms with 1 or 2 substituents R^{1a} which are the same or different, wherein R^{1a} represents C_1-C_5-alkyl, C_3-C_7-cycloalkyl, -(C_1-C_3-alkyl)-(C_3-C_7-cycloalkyl), -OC_1-C_5-alkyl, -OC_3-C_7-cycloalkyl, halogen or CN,

wherein independently each nitrogen atom of said R^1 is optionally substituted with a substituent R^{1b}, wherein R^{1b} represents C_1-C_5-alkyl, -(C_1-C_3-alkyl)-(C_3-C_7-cycloalkyl) or C_3-C_7-cycloalkyl, and

if R^{1a} represents C_1-C_5-alkyl, C_3-C_7-cycloalkyl, -(C_1-C_3-alkyl)-(C_3-C_7-cycloalkyl), -OC_1-C_5-alkyl or -OC_3-C_7-cycloalkyl and/or if R^{1b} represents C_1-C_5-alkyl, -(C_1-C_3-alkyl)-(C_3-C_7-cycloalkyl) or C_3-C_7-cycloalkyl, said C_1-C_5-alkyl, C_3-C_7-cycloalkyl, -(C_1-C_3-alkyl)-(C_3-C_7-cycloalkyl), -OC_1-C_5-alkyl and -OC_3-C_7-cycloalkyl independently are optionally substituted with one or more substituents independently selected from the group consisting of methyl, OH, OR^4 and F;

R^2 represents phenyl substituted with 1 or 2 substituents R^{2a} which are the same or different, wherein R^{2a} represents C_1-C_5-alkyl, -OC_1-C_5-alkyl, F or Cl,

wherein if the substituent or at least one of said substituents is C_1-C_5-alkyl, -OC_1-C_5-alkyl or Cl, it is preferably positioned para to the carbon atom which links the phenyl to the rest of the molecule, and

wherein said C_1-C_5-alkyl and -OC_1-C_5-alkyl independently are optionally substituted with 1 to 5 fluorine atoms;

R^5 represents H, F, Cl or methyl, in particular H or F; and

R^6 and R^7 represent H;

or an enantiomer diastereomer, racemate, hydrate, solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of the same.

9. The compound according to any one of claims 1 to 8, wherein

R^1 represents pyrazol-4-yl, substituted at the nitrogen atom at position 1 with a substituent R^{1b}, wherein R^{1b} represents C_1-C_5-alkyl, -(C_1-C_3-alkyl)-(C_3-C_7-cycloalkyl) or C_3-C_7-cycloalkyl,

wherein said R^{1b} is optionally substituted with one or more substituents independently selected from the group consisting of methyl, OH, OR^4 and F;

R^2 represents phenyl substituted with 1 or 2 substituents R^{2a} which are the same or different, wherein R^{2a} represents methyl, trifluoromethyl, trifluoromethoxy, F or Cl, and

wherein if the substituent or at least one of said substituents is F, it is preferably positioned ortho to the carbon atom which links the phenyl to the rest of the molecule, and

wherein if the substituent or at least one of said substituents is methyl, trifluoromethyl, trifluoromethoxy or Cl, it is preferably positioned para to the carbon atom which links the phenyl to the rest of the molecule;

R^5 represents H, F, Cl or methyl, in particular H or F; and

R^6 and R^7 represent H;

or an enantiomer diastereomer, racemate, hydrate, solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of the same.

10. The compound according to any one of claims 1 to 9, wherein

R^3 represents H; and

R^5 represents H;

or an enantiomer diastereomer, racemate, hydrate, solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of the same.

11. The compound according to any one of claim 1 to 9, wherein

R^3 represents H; and

R^5 represents F;

or an enantiomer diastereomer, racemate, hydrate, solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of the same.

12. The compound according to any one of claim 1 to 10, wherein

R^1 represents pyrazol-4-yl substituted at the nitrogen atom at position 1 with a substituent selected from the group consisting of methyl, ethyl, propyl, propan-2-yl, 2-methylpropyl, tertbutyl, butan-2-yl, cyclobutyl, 2,2-dimethylpropyl, 3-methylbutan-2-yl, cyclopentyl, cyclohexyl, 1-cyclopropylmethyl, 1-cyclopropylethyl, 1-cyclobutylmethyl, 1-(1-methylcyclopropyl)methyl and 2,2,2-trifluoroethyl, in particular ethyl, propan-2-yl, 2-methylpropyl, butan-2-yl, cyclobutyl, 2,2-dimethylpropyl, 1-cyclopropylmethyl, 1-cyclopropylethyl, 1-(1-methylcyclopropyl)methyl, and 1-cyclobutylmethyl;

R^2 represents phenyl substituted with 1 or 2 substituents R^{2a} which are the same or different, wherein R^{2a} represents methyl, trifluoromethyl, trifluoromethoxy, F or Cl,

wherein if the substituent or at least one of said substituents is F , it is preferably positioned ortho to the carbon atom which links the phenyl to the rest of the molecule, and

wherein if the substituent or at least one of said substituents is methyl, trifluoromethyl, trifluoromethoxy or Cl, it is preferably positioned para to the carbon atom which links the phenyl to the rest of the molecule;

R^3 represents H;

R^5 represents H or F, preferably H; and

R^6 and R^7 represent H;

or an enantiomer diastereomer, racemate, hydrate, solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of the same.

13. The compound according to any one of claims 1 or 2, wherein

R^1 represents thiazol-5-yl, optionally substituted at the carbon atom at position 2 with a substituent R^{1a} selected from the group consisting of methyl, ethyl, propyl, propan-2-yl, cyclopropyl, 2-methylpropyl, tertbutyl, butan-2-yl, cyclobutyl, 2,2-dimethylpropyl, 3-methylbutan-2-yl, cyclopentyl, cyclohexyl, 1-cyclopropylmethyl, 1-cyclopropylethyl, 1-cyclobutylmethyl, 1-(1-methylcyclopropyl)methyl and 2,2,2-trifluoroethyl, in particular ethyl, propan-2-yl, 2-methylpropyl, butan-2-yl, cyclobutyl, 2,2-dimethylpropyl, cyclopentyl, 1-cyclopropylmethyl, 1-cyclopropylethyl, 1-(1-methylcyclopropyl)methyl and 1-cyclobutylmethyl;

R^2 represents phenyl substituted with 1 or 2 substituents R^{2a} which are the same or different, wherein R^{2a} represents methyl, trifluoromethyl, trifluoromethoxy, F or Cl, and

wherein if the substituent or at least one of said substituents is F, it is preferably positioned ortho to the carbon atom which links the phenyl to the rest of the molecule, and

wherein if the substituent or at least one of said substituents is methyl, trifluoromethyl, trifluoromethoxy or Cl, it is preferably positioned para to the carbon atom which links the phenyl to the rest of the molecule;

R^5 represents H, F, Cl or methyl, in particular H or F; and

R^6 and R^7 represent H;

or an enantiomer diastereomer, racemate, hydrate, solvate, or a salt thereof, particularly a pharmaceutically acceptable salt thereof, or a mixture of the same.

14. The compound according to any one of claims 1 to 13 selected from the group consisting of

2-(1-benzothiophen-2-yl)-5-[({1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropyl}carbonyl)amino]benzoic acid;

2-[6-(1,1-difluoropropyl)pyridin-3-yl]-5-[({1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropyl}carbonyl)amino]benzoic acid;

2-(1-cyclobutyl-1H-pyrazol-4-yl)-5-[({1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropyl}carbonyl)amino]benzoic acid;

2-(6-ethoxypyridin-3-yl)-5-[({1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropyl}carbonyl)amino]benzoic acid;

2-(6-ethoxypyridin-3-yl)-5-[({1-[2-fluoro-4-(trifluoromethoxy)phenyl]cyclopropyl}carbonyl)amino]benzoic acid;

2-(1-cyclobutyl-1H-pyrazol-4-yl)-3-fluoro-5-({[1-(2-fluoro-4-methylphenyl)cyclopropyl]carbonyl}amino)benzoic acid;

2-[6-(1,1-difluoropropyl)pyridin-3-yl]-5-[({1-[2-fluoro-4-(trifluoromethoxy)phenyl]cyclopropyl}carbonyl)amino]benzoic acid;

3-fluoro-5-[({1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropyl}carbonyl)amino]-2-[6-(trifluoromethyl)pyridin-3-yl]benzoic acid;

5-[({1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropyl}carbonyl)amino]-2-[1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl]benzoic acid;

5-({[1-(4-chlorophenyl)cyclopropyl]carbonyl}amino)-2-(1-cyclobutyl-1H-pyrazol-4-yl)-3-fluorobenzoic acid;

2-(1-cyclobutyl-1H-pyrazol-4-yl)-3-fluoro-5-[({1-[4-(trifluoromethyl)phenyl]cyclopropyl}carbonyl)amino]benzoic acid;

2-(1-cyclobutyl-1H-pyrazol-4-yl)-3-fluoro-5-[({1-[4-(trifluoromethoxy)phenyl]cyclopropyl}carbonyl)amino]benzoic acid;

2-(1-cyclobutyl-1H-pyrazol-4-yl)-5-({[1-(3,4-difluorophenyl)cyclopropyl]carbonyl}amino)-3-fluorobenzoic acid;

2-(1-cyclobutyl-1H-pyrazol-4-yl)-3-fluoro-5-[({1-[3-fluoro-4-(trifluoromethyl)phenyl]cyclopropyl}carbonyl)amino]benzoic acid;

2-(1-cyclobutyl-1H-pyrazol-4-yl)-5-({[1-(2,4-difluorophenyl)cyclopropyl]carbonyl}amino)-3-fluorobenzoic acid;

5-({[1-(4-chloro-2-fluorophenyl)cyclopropyl]carbonyl}amino)-2-(1-cyclobutyl-1H-pyrazol-4-yl)-3-fluorobenzoic acid;

2-(1-cyclobutyl-1H-pyrazol-4-yl)-3-fluoro-5-[({1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropyl}cabonyl)amino]benzoic acid;

2-(1-cyclobutyl-1H-pyrazol-4-yl)-3-fluoro-5-[({1-[2-fluoro-4-(trifluoromethoxy)phenyl]cyclopropyl}carbonyl)amino]benzoic acid;

2-(1-cyclobutyl-1H-pyrazol-4-yl)-3-fluoro-5-({[1-(5-fluoropyridin-2-yl)cyclopropyl]carbonyl}amino)benzoic acid;

2-(1-cyclobutyl-3-fluoro-1H-pyrazol-4-yl)-5-[({1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropyl}carbonyl)amino]benzoic acid;

5-({[1-(4-chloro-3-fluorophenyl)cyclopropyl]carbonyl}amino)-2-(1-cyclobutyl-1H-pyrazol-4-yl)benzoic acid;

2-(1-cyclobutyl-1H-pyrazol-4-yl)-5-[({1-[2-fluoro-4-(trifluoromethoxy)phenyl]cyclopropyl}carbonyl)amino]benzoic acid;

5-({[1-(4-chloro-2-fluorophenyl)cyclopropyl]carbonyl}amino)-2-(1-cyclobutyl-1H-pyrazol-4-yl)benzoic acid;

5-({[1-(5-chloro-2-fluorophenyl)cyclopropyl]carbonyl}amino)-2-(1-cyclobutyl-1H-pyrazol-4-yl)benzoic acid;

2-(1-ethyl-1H-pyrazol-4-yl)-5-[({1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropyl}carbonyl)amino]benzoic acid;

2-(1-ethyl-1H-pyrazol-4-yl)-5-[({1-[2-fluoro-4-(trifluoromethoxy)phenyl]cyclopropyl}carbonyl)amino]benzoic acid;

5-[({1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropyl}carbonyl)amino]-2-[1-(propan-2-yl)-1H-pyrazol-4-yl]benzoic acid;

5-[({1-[2-fluoro-4-(trifluoromethoxy)phenyl]cyclopropyl}carbonyl)amino]-2-[1-(propan-2-yl)-1H-pyrazol-4-yl]benzoic acid;

2-(1-tert-butyl-1H-pyrazol-4-yl)-5-[({1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropyl}carbonyl)amino]benzoic acid;

2-(1-tert-butyl-1H-pyrazol-4-yl)-5-[({1-[2-fluoro-4-(trifluoromethoxy)phenyl]cyclopropyl}carbonyl)amino]benzoic acid;

5-[({1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropyl}carbonyl)amino]-2-[1-(2-methylpropyl)-1H-pyrazol-4-yl]benzoic acid;

5-[({1-[2-fluoro-4-(trifluoromethoxy)phenyl]cyclopropyl}carbonyl)amino]-2-[1-(2-methylpropyl)-1H-pyrazol-4-yl]benzoic acid;

2-[1-(2,2-dimethylpropyl)-1H-pyrazol-4-yl]-5-[({1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropyl}carbonyl)amino]benzoic acid;

2-[1-(2,2-dimethylpropyl)-1H-pyrazol-4-yl]-5-[({1-[2-fluoro-4-(trifluoromethoxy)phenyl]cyclopropyl}carbonyl)amino]benzoic acid;

3-fluoro-5-({[1-(2-fluoro-4-methylphenyl)cyclopropyl]carbonyl}amino)-2-[1-(propan-2-yl)-1H-pyrazol-4-yl]benzoic acid;

3-fluoro-5-[({1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropyl}carbonyl)amino]-2-[1-(propan-2-yl)-1H-pyrazol-4-yl]benzoic acid;

3-fluoro-5-[({1-[2-fluoro-4-(trifluoromethoxy)phenyl]cyclopropyl}carbonyl)amino]-2-[1-(propan-2-yl)-1H-pyrazol-4-yl]benzoic acid;

2-(4-tert-butyl-1H-imidazol-1-yl)-3-fluoro-5-[({1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropyl}carbonyl)amino]benzoic acid;

2-(4-tert-butyl-1H-imidazol-1-yl)-3-fluoro-5-[({1-[2-fluoro-4-(trifluoromethoxy)phenyl]cyclopropyl}carbonyl)amino]benzoic acid;

3-fluoro-5-[({1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropyl}carbonyl)amino]-2-[1-(2-methylpropyl)-1H-pyrazol-4-yl]benzoic acid;

2-[6-(difluoromethyl)pyridin-3-yl]-3-fluoro-5-[({1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropyl}carbonyl)amino]benzoic acid;

2-[6-(difluoromethyl)pyridin-3-yl]-3-fluoro-5-[({1-[2-fluoro-4-(trifluoromethoxy)phenyl]cyclopropyl}carbonyl)amino]benzoic acid;

2-[6-(1,1-difluoropropyl)pyridin-3-yl]-3-fluoro-5-[({1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropyl}carbonyl)amino]benzoic acid;

2-[6-(1,1-difluoropropyl)pyridin-3-yl]-3-fluoro-5-[({1-[2-fluoro-4-(trifluoromethoxy)phenyl]cyclopropyl}carbonyl)amino]benzoic acid;

3-chloro-2-(1-cyclobutyl-1H-pyrazol-4-yl)-5-[({1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropyl}carbonyl)amino]benzoic acid;

3-chloro-2-(1-cyclobutyl-1H-pyrazol-4-yl)-5-[({1-[2-fluoro-4-(trifluoromethoxy)phenyl]cyclopropyl}carbonyl)amino]benzoic acid;

3-chloro-2-[6-(1,1-difluoropropyl)pyridin-3-yl]-5-[({1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropyl}carbonyl)amino]benzoic acid;

3-chloro-2-[6-(1,1-difluoropropyl)pyridin-3-yl]-5-[({1-[2-fluoro-4-(trifluoromethoxy)phenyl]cyclopropyl}carbonyl)amino]benzoic acid;

2-(1-cyclobutyl-1H-pyrazol-4-yl)-5-[({1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropyl}carbonyl)amino]-3-methylbenzoic acid;

2-(1-cyclobutyl-1H-pyrazol-4-yl)-5-[({1-[2-fluoro-4-(trifluoromethoxy)phenyl]cyclopropyl}carbonyl)amino]-3-methylbenzoic acid;

2-[1-(cyclobutylmethyl)-1H-pyrazol-4-yl]-5-[({1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropyl}carbonyl)amino]benzoic acid;

2-[1-(cyclobutylmethyl)-1H-pyrazol-4-yl]-5-[({1-[2-fluoro-4-(trifluoromethoxy)phenyl]cyclopropyl}carbonyl)amino]benzoic acid;

2-(1-cyclopentyl-1H-pyrazol-4-yl)-5-[({1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropyl}carbonyl)amino]benzoic acid;

2-(1-cyclohexyl-1H-pyrazol-4-yl)-5-[({1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropyl}carbonyl)amino]benzoic acid;

2-(1-cyclohexyl-1H-pyrazol-4-yl)-5-[({1-[2-fluoro-4-(trifluoromethoxy)phenyl]cyclopropyl}carbonyl)amino]benzoic acid;

2-[1-(cyclopropylmethyl)-1H-pyrazol-4-yl]-3-fluoro-5-[({1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropyl}carbonyl)amino]benzoic acid;

2-[1-(cyclopropylmethyl)-1H-pyrazol-4-yl]-3-fluoro-5-[({1-[2-fluoro-4-(trifluoromethoxy)phenyl]cyclopropyl}carbonyl)amino]benzoic acid;

3-fluoro-5-[({1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropyl}carbonyl)amino]-2-(6-methylpyridin-3-yl)benzoic acid;

2-{1-[(2S)-butan-2-yl]-1H-pyrazol-4-yl}-5-[({1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropyl}carbonyl)amino]benzoic acid;

2-{1-[(2R)-butan-2-yl]-1H-pyrazol-4-yl}-5-[({1-[2-fluoro-4-(trifluoromethoxy)phenyl]cyclopropyl}carbonyl)amino]benzoic acid;

2-{1-[(2S)-butan-2-yl]-1H-pyrazol-4-yl}-3-fluoro-5-[({1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropyl}carbonyl)amino]benzoic acid;

2-{1-[(2R)-butan-2-yl]-1H-pyrazol-4-yl}-3-fluoro-5-[({1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropyl}carbonyl)amino]benzoic acid;

2-(1-ethyl-1H-pyrazol-4-yl)-3-fluoro-5-[({1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropyl}carbonyl)amino]benzoic acid;

2-(1-ethyl-1H-pyrazol-4-yl)-3-fluoro-5-[({1-[2-fluoro-4-(trifluoromethoxy)phenyl]cyclopropyl}carbonyl)amino]benzoic acid;

5-({[1-(4-chloro-2-fluorophenyl)cyclopropyl]carbonyl}amino)-3-fluoro-2-[1-(propan-2-yl)-1H-pyrazol-4-yl]benzoic acid;

5-({[1-(4-chloro-2-fluorophenyl)cyclopropyl]carbonyl}amino)-2-(2-cyclobutyl-1,3-thiazol-5-yl)benzoic acid;

2-(2-cyclobutyl-1,3-thiazol-5-yl)-5-({[1-(2-fluoro-4-methylphenyl)cyclopropyl]carbonyl}amino)benzoic acid;

2-(2-cyclobutyl-1,3-thiazol-5-yl)-5-[({1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropyl}carbonyl)amino]benzoic acid;

2-(2-cyclobutyl-1,3-thiazol-5-yl)-5-[({1-[2-fluoro-4-(trifluoromethoxy)phenyl]cyclopropyl}carbonyl)amino]benzoic acid;

5-[({1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropyl}carbonyl)amino]-2-{1-[(1-methylcyclopropyl)methyl]-1H-pyrazol-4-yl}benzoic acid;

5-[({1-[2-fluoro-4-(trifluoromethoxy)phenyl]cyclopropyl}carbonyl)amino]-2-{1-[(1-methylcyclopropyl)methyl]-1H-pyrazol-4-yl}benzoic acid;

2-{1-[(1S)-1-cyclopropylethyl]-1H-pyrazol-4-yl}-5-[({1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropyl}carbonyl)amino]benzoic acid;

2-(6-ethylpyridin-3-yl)-5-[({1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropyl}carbonyl)amino]benzoic acid;

2-(6-ethylpyridin-3-yl)-5-[({1-[2-fluoro-4-(trifluoromethoxy)phenyl]cyclopropyl}carbonyl)amino]benzoic acid;

2-(6-ethylpyridin-3-yl)-3-fluoro-5-[({1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropyl}carbonyl)amino]benzoic acid;

3-fluoro-5-[({1-[2-fluoro-4-(trifluoromethoxy)phenyl]cyclopropyl}carbonyl)amino]-2-(1-methyl-1H-indazol-6-yl)benzoic acid;

2-(2-cyclopentyl-1,3-thiazol-5-yl)-5-[({1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropyl}carbonyl)amino]benzoic acid;

2-(2-cyclobutyl-1,3-thiazol-5-yl)-3-fluoro-5-[({1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropyl}carbonyl)amino]benzoic acid; and

3-fluoro-5-[({1-[2-fluoro-4-(trifluoromethyl)phenyl]cyclopropyl}carbonyl)amino]-2-[1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl]benzoic acid;

or a pharmaceutically acceptable salt thereof.

15. A pharmaceutical composition comprising a compound according to any one of claims 1 to 14, and a pharmaceutically acceptable diluent or carrier.

16. A compound according to any one of claims 1 to 14, or a pharmaceutical composition of claim 15 for use in the treatment or prophylaxis of a disease or disease syndromes, conditions, or symptoms.

17. Use of a compound according to any one of claims 1 to 14, or a pharmaceutical composition of claim 15 in the manufacture of a medicament for the treatment or prophylaxis of a disease or disease syndromes, conditions, or symptoms, wherein said disease or disease syndromes, conditions, or symptoms are associated with pain and/or inflammation.

18. The use according to claim 17, wherein said disease or disease syndromes, conditions, or symptoms are associated with pain selected from the group consisting of

- visceral pain e.g. related to pancreatitis, interstitial cystitis, bladder pain syndrome, renal colic, or prostatitis, chronic pelvic pain, or pain related to infiltrating endometriosis;
- neuropathic pain such as post herpetic neuralgia, acute zoster pain, pain related to nerve injury, the dynias, including vulvodynia, phantom limb pain, pain related to root avulsions, pain related to radiculopathy, painful traumatic mononeuropathy, painful entrapment neuropathy, pain related to carpal tunnel syndrome, ulnar neuropathy, pain related to tarsal tunnel syndrome, painful diabetic neuropathy, painful polyneuropathy, trigeminal neuralgia, or pain related to familial amyloid polyneuropathy;
- central pain syndromes potentially caused by virtually any lesion at any level of the nervous system including but not limited to pain related to stroke, multiple sclerosis, and spinal cord injury;
- postsurgical pain syndromes (including postmastectomy pain syndrome, postthoracotomy pain syndrome, stump pain), bone and joint pain (osteoarthritis), spine pain (including acute and chronic low back pain, neck pain, pain related to spinal stenosis), shoulder pain, repetitive motion pain, dental pain, pain related to sore throat, cancer pain, burn pain including sun-burn pain, myofascial pain (pain related to muscular injury, fibromyalgia), postoperative and perioperative pain (including but not limited to general surgery, orthopaedic, and gynaecological surgery); and

- acute and chronic pain, chronic pelvic pain, endometriosis associated pain, dysmenorrhea associated pain (primary and secondary), pain associated with uterine fibroids, vulvodynia associated pain, as well as pain associated with angina, or inflammatory pain of varied origins (including but not limited to pain associated with osteoarthritis, rheumatoid arthritis, rheumatic disease, tenosynovitis, gout, ankylosing spondylitis, and bursitis).

19. The use according to claim 17, wherein said disease or disease syndromes, conditions, or symptoms are selected from or related to any one of the group consisting of

- gynaecological disorders and/ or diseases, or effects and/ or symptoms which negatively influence women health including endometriosis, uterine fibroids, pre-eclampsia, hormonal deficiency, spasms of the uterus, or heavy menstrual bleeding;
- the respiratory or excretion system including any of inflammatory hyperreactive airways, inflammatory events associated with airways disease like chronic obstructive pulmonary disease, asthma including allergic asthma (atopic or non-atopic) as well as exercise-induced bronchoconstriction, occupational asthma, viral or bacterial exacerbation of asthma, other non-allergic asthmas and wheezy-infant syndrome, chronic obstructive pulmonary disease including emphysema, adult respiratory distress syndrome, bronchitis, pneumonia, cough, lung injury, lung fibrosis, allergic rhinitis (seasonal and perennial), vasomotor rhinitis, angioedema (including hereditary angioedema and drug-induced angioedema including that caused by angiotensin converting enzyme (ACE) or ACE/neutral endopeptidase inhibitors like omepatrilat), pneumoconiosis, including aluminosis, anthracosis, asbestosis, chalicosis, ptilosis, siderosis, silicosis, tabacosis and byssinosis, bowel disease including Crohn's disease and ulcerative colitis, irritable bowel syndrome, pancreatitis, nephritis, cystitis (interstitial cystitis), bladder pain syndrome, kidney fibrosis, kidney failure, hyperactive bladder, and overactive bladder;
- dermatology including pruritus, itch, inflammatory skin disorders including psoriasis, eczema, and atopic dermatitis;

- affection of the joints or bones including rheumatoid arthritis, gout, osteoporosis, osteoarthritis, and ankylosing spondylitis;
- affection of the central and peripheral nervous system including neurodegenerative diseases including Parkinson's and Alzheimer's disease, amyotrophic lateral sclerosis (ALS), epilepsy, dementia, headache including cluster headache, migraine including prophylactic and acute use, stroke, closed head trauma, and multiple sclerosis;
- infection including HIV infection, and tuberculosis;
- trauma associated with oedema including cerebral oedema, burns, sunburns, and sprains or fracture;
- poisoning including aluminosis, anthracosis, asbestosis, chalicosis, ptilosis, siderosis, silicosis, tabacosis, and byssinosis uveitis;
- diabetes cluster or metabolism like diabetes type 1, diabetes type 2, diabetic vasculopathy, diabetic neuropathy, diabetic retinopathy, post capillary resistance or diabetic symptoms associated with insulitis (e.g. hyperglycaemia, diuresis, proteinuria and increased nitrite and kallikrein urinary excretion), diabetic macular oedema, metabolic syndrome, insulin resistance, obesity, or fat or muscle metabolism;
- cachexia associated with or induced by any of cancer, AIDS, coeliac disease, chronic obstructive pulmonary disease, multiple sclerosis, rheumatoid arthritis, congestive heart failure, tuberculosis, familial amyloid polyneuropathy, mercury poisoning (acrodynia), and hormonal deficiency;
- cardio-vascular system including congestive heart failure, atherosclerosis, congestive heart failure, myocardial infarct, and heart fibrosis; and
- other conditions including primary peritonitis, secondary peritonitis, septic shock, sepsis, muscle atrophy, spasms of the gastrointestinal tract, benign prostatic hyperplasia, and liver diseases such as non-alcoholic and alcoholic fatty liver disease, non-alcoholic and alcoholic steatohepatitis, liver fibrosis, or liver cirrhosis.

20. The use according to claim 19 wherein said disease or disease syndromes, conditions, or symptoms is related to endometriosis or endometriosis-associated pain, in particular to dysmenorrhea, dyspareunia, dysuria, or dyschezia.

21. The use according to claim 19 wherein said disease or disease syndromes, conditions, or symptoms are selected from or related to overactive bladder, fibrosis of lung, kidney, heart and/or liver, diabetes type 1 and/or type 2, metabolic syndrome, gout, rheumatoid arthritis, and osteoarthritis including the related symptoms.